Introduction

Human gliomas are the most frequent and most aggressive primary brain tumor that exhibits malignant aggressiveness and poor prognosis [1, 2]. Currently, although surgical operation combined with radiotherapy and chemotherapy are effective remedies for the treatment of primary glioma, the prognosis of glioma patients still remains poor, with a median survival time of about 12 months [3, 4]. Temozolomide (TMZ) is a second generation of alkylating agent that induces apoptosis via methylation of guanine residues [5]. TMZ concurrently and after radiotherapy significantly improves the overall survival compared with radiation therapy alone and has the advantage of wide applicability and minimal additional toxicity [6, 7]. It has become the current standard chemotherapeutic drug in the treatment for glioma. However, the development of inherent or acquired TMZ resistance limits its clinical application, and the mechanisms of TMZ resistance are not fully understood [8, 9]. Thus, identification of new molecular targets is urgently required to fight against TMZ resistance in glioma.

Abstract

The occurrence of an inherent or acquired resistance to temozolomide (TMZ) is a major burden for patients suffering from glioma. Recently, studies have demonstrated that microRNAs play an important role in the regulation of tumor properties in cancers. However, whether miR-497 contributes to glioma resistance to chemotherapy is not fully understood. In this study, we showed that the expression of miR-497 was markedly up-regulated in TMZ-resistant glioma cells; high miR-497 expression level was associated with TMZ-resistant phenotype of glioma cells. The down-regulation of miR-497 in glioma cells enhanced the apoptosis-induction and growth inhibition effects of TMZ both in vitro and in vivo, whereas promotion of miR-497 increased the chemosensitization of glioma cells to TMZ. The increased level of miR-497 in TMZ-resistant glioma cells was concurrent with the up-regulation of insulin-like growth factor 1 receptor (IGF1R)/insulin receptor substrate 1 (IRS1) pathway-related proteins, that is, IGF1R, IRS1, mammalian target of rapamycin (mTOR), and Bcl-2. In addition, the knockdown of mTOR and Bcl-2 reduced the tolerance of glioma cells to TMZ. Our results demonstrated that overexpression of miR-497 is significantly correlated with TMZ resistance in glioma cells by regulating the IGF1R/IRS1 pathway. Therefore, miR-497 may be used as a new target for treatment of chemotherapy-resistant glioma.
tumorigenesis [10, 11]. Recent evidence has shown that miRNAs also plays a vital role in chemotherapeutic resistance. For instance, miR-873 was found to improve the chemosensitivity of glioblastoma cells to cisplatin by targeting Bcl-2 [12]. MiR-16 was reported to mediate TMZ resistance in glioma cells by modulation of apoptosis [13], highlighting miRNAs as potent chemo-resistant modulators in the treatment of glioma.

MiR-497 is found as a tumor suppressive miRNA in most human cancer. Such function is exerted partly by its anti-proliferative and anti-growth potential [14–17]. Previous study showed that miR-497 induced breast cancer cell apoptosis by negatively regulating Bcl-2 protein expression [18]. Recent studies found that overexpression of miR-497 decreases cisplatin resistance of ovarian cancer cells in vitro and in vivo [15].

However, whether miR-497 regulates other target genes to mediate glioma cell growth is still unknown, and the relationship between miR-497 and chemotherapeutical resistance in glioma cells is not fully elucidated. This study was designed to investigate the molecular mechanisms of miR-497 in TMZ-resistant glioma.

**Materials and Methods**

**Cell culture and reagents**

Six human glioma cell lines (SF295, SHG-44, U138, LN382, U87, and U251), HEK-293 T-cell line, and the normal human astrocytes (NHA) were all purchased from American Type Culture Collection (ATCC, Rockville, MD). The cells were routinely cultured in Dulbecco’s Modified Eagle Medium (Gibco, NY) supplemented with 10% fetal bovine serum (Gibco, NY), 0.5% penicillin-streptomycin, and 1% glutamine at 37°C in a humidified environment containing 5% CO₂. Antibodies against mammalian target of rapamycin (mTOR), Bcl-2 (Sigma, St Louis, MO), insulin-like growth factor 1 receptor α (IGF1Rα), insulin receptor substrate 1 (IRS1) (Abcam, Cambridge, MA), and β-actin (Sigma) were used.

**Generation of stable transformants**

Lentiviral constructs containing hsa-miR-497 (Lenti-miR-497) and anti-miR-497 (Lenti-anti-miR-497) along with their matched negative controls (Lenti-miR-NC or Lenti-anti-miR-NC) were synthesized by Ambion Austin (TX). Short interfering (siRNA) targeting mTOR and Bcl-2 were purchased from Thermo Scientific Waltham, MA, as specific oligo pools. mTOR and Bcl-2 overexpressing vectors and their matched negative controls were purchased from Clontech Laboratories, Inc Mountain View, CA. Briefly, when cells were grown to 40–50% confluence in 6-well plates, the cells were transfected using lipofectamine 2000 (Invitrogen, Carlsbad CA) according to the manufacturer’s protocol. Complete media was changed 5 h after transfection.

**Generation of TMZ-resistant glioma cell lines**

To establish the TMZ-resistant glioma cell lines, U87 and SF295 cells were exposed to gradually increasing concentrations of TMZ (5–100 μmol/L) in culture media for 6 months as described previously [13]. The generated TMZ-resistant cell lines were named as U87-TR and SF295-TR.

**Cell viability assay**

Cells were seeded in each well of 96-well plates (5 × 10³ cells/well). After overnight incubation, medium was removed and replaced with fresh culture medium. After 48 h of incubation, 10 μL cell counting kit-8 (CCK-8) solution (Dojin Laboratory, Kumamoto, Japan) was added to each well 1 h before the end of culture, then the absorbance was measured at 490 nm using a microplate spectrophotometer (Bio-Tek, Burlington USA).

**Apoptotic cell determination**

Cells were harvested and fixed for 20 min in PBS containing 1% glutaraldehyde. Then the cells were permeabilized with 0.1% Triton X-100 and stained with 1 mmol/L of Hochest 33258, and the nuclei were observed under a fluorescence microscope (Olympus, Tokyo, Japan).

**Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)**

The total RNA was extracted by Trizol Reagent (Life Technologies, Carlsbad, CA). The cDNA was produced using 1 μg of total RNA according to the protocol for miScript II RT Kit (Qiagen, Hilden, Germany). Real-time PCR was performed on the 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA). GAPDH was used as endogenous controls for miRNAs expression. The relative expression of mRNA in each sample was calculated using the 2^ΔΔCt method [24].

**Western blot analysis**

Cells were harvested with 1× radioimmunoprecipitation assay lysis buffer (Thermo Scientific) with protease inhibitor cocktail (1×; Sigma-Aldrich St. Louis, Missouri). Homogenates were incubated on ice for 15 min and then centrifuged at 16,099 g for 10 min. The supernatant containing cell
proteins was collected and stored at −80°C. Cell lysates were measured by Bradford assay and then were loaded on sodium dodecyl sulfate–polyacrylamide gel electrophoresis gels. Membranes were blocked overnight at 4°C using 5% non-fat dry milk in Tris-buffered saline for 1 h and incubated with primary antibodies overnight at 4°C. Afterward, they were probed again with respective secondary antibodies (Sigma). Band signals were visualized using an enhanced chemiluminescence kit (Pierce, Minneapolis, MN). The same membrane was reprobed with the β-actin antibody, which was used as the internal control.

In vivo tumorigenesis

To confirm the function of miR-497 in vivo, 1 × 10⁷ logarithmically growing U87 cells stably transfected with lenti-anti-NC or lenti-anti-miR-497 were injected subcutaneously into the right armpit of 18–26 g male BALB/c nude mice. Four days after the implantation, the mice were randomly divided into two groups, five mice per group. Mice in both groups were orally treated with 10 mg/kg TMZ for 8 days continuously. At 56 days after inoculation, all mice were killed, while the tumors were excised, weighed, photographed, and subjected to western blot. All animal procedures were approved by the Ethics Animal Care and Use Committee of The First Affiliated Hospital of Wenzhou Medical University.

Immunolocalization of Ki-67 in tumor samples

Xenograft tumor tissues of all mice from both the anti-NC and anti-miR-497 groups were embedded in paraffin and fixed with formaldehyde. Such samples were sectioned, and immunostaining was performed using specific antibody against Ki-67 with appropriate dilution and using normal host serum as a negative control, followed by staining with appropriate HRP-conjugated secondary antibody. The slides were developed in 3-3′-diaminobenzidinetetrahydrochloride solution and counterstained with a weak hematoxylin solution stain. The stained sections were counted in 10 random views at 400× magnification by two different pathologists who remained blind to the xenograft tumor groups. Staining intensity was semiquantified in 20 randomly selected fields per tumor, and the proliferation index was expressed as Ki-67-positive cells/total cells in the view × 100%.

TUNEL labeling assay

Apoptotic cells were detected using the in situ cell death assay kit from Roche diagnostics as per manufacturer’s instructions. The apoptosis index was calculated as the percentage of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-labeled cells and was obtained by counting 20 randomly chosen visual fields of the most affected tumor areas under a microscope.

Statistical analysis

Data were expressed as mean ± standard deviation values or percent of controls. Statistical differences were evaluated by one-way analysis of variance (ANOVA) followed by dunnett-t multiple comparisons tests. All calculations were performed with the SPSS software (version 15.0, SPSS, Inc. Chicago, Illinois). P < 0.05 was considered to be statistically significant.

Results

Establishment and characterization of TMZ-resistant glioma cell lines

To elucidate the TMZ resistance in glioma cell lines, the initial experiment was focused on the sensitivity of TMZ in six glioma cell lines. Our results showed that two of them SF295 and U87, exhibited a lower IC50 than the other cell lines U138, LN382, SHG-44, and U251 (Fig. 2A). Next, by exposing U87 and SF295 cells to increasing concentrations of TMZ for 6 months, we were able to establish two resistant glioma cell lines to TMZ (U87-TR and SF295-TR). Thus, this resistance phenotype was stable and cell autonomous, as it was not reversed by culturing U87-TR or SF295-TR cells in TMZ-free medium for up to 6 months. These U87-TR and SF295-TR cell lines are ~9 times and 7 times resistant to TMZ compared with their parental cell lines, respectively (Fig. 1B).

Analysis of miR-497 in glioma cell lines

To investigate the function of miR-497 on TMZ sensitivity in glioma cells, we examined the relative expression of miR-497 in several glioma cell lines as well as NHA, which is a NHA by qRT-PCR. The results demonstrated that the expression of miR-497 was increased in all the six glioma cell lines than that in NHA (Fig. 2A). Furthermore, the correlation between the relative miR-497 level and IC50 values was analyzed. Interestingly, the abundance of miR-497 was positively correlated with IC50 values in glioma cell lines. Investigations into such information indicated that miR-497 was closely associated with TMZ sensitivity in glioma cells. We next evaluated whether acquired resistance to TMZ impacted the level of miR-497 in glioma cells. Our results show that the level of miR-497 was up-regulated in U87-TR and SF295-TR cell lines compared with their matched parental cell lines (Fig. 2B).
Effect of miR-497 on the TMZ resistance of glioma cells

To determine the role of miR-497 in TMZ-resistant phenotype of glioma cells, the expression of miR-497 in U87-TR and SF295-TR cells with high endogenous miR-497 levels was down-regulated by the transfection of cells with anti-miR-497 or anti-miR-NC. We also promoted the expression of miR-497 in U87 and SF295 cells after transfecting with miR-497 or negative control. As a result, the expression of miR-497 was decreased significantly after the glioma cells were transfected with anti-miR-497. Moreover, transfection of miR-497 led to a significant increase in its expression (Fig. 2C). Additionally, the effects of miR-497 or anti-miR-497 on the proliferation of glioma cells were investigated. As shown in Figure 2D, the result of CCK-8 assay indicated that the down-regulation of miR-497 significantly reduced U87-TR and SF295-TR cells resistance to TMZ. On the contrary, the up-regulation of miR-497 dramatically increased U87 and SF295 cells tolerance to TMZ. We further examined the cellular apoptosis by Hochest 33258 staining assay in miR-497-depleted U87-TR and miR-497-overexpressed SF295 cells. Our data showed clearly that the inhibition of miR-497 promoted apoptosis induced by TMZ in U87-TR cells (Fig. 2E). However, the ectopic miR-497 prevented the percentage of apoptotic cells in SF295 cells induced by TMZ (Fig. 2F). These data suggest that miR-497 plays a crucial role in the development of TMZ resistance in glioma cells in vitro.

MiR-497 directly targets mTOR/Bcl-2

To explore the molecular mechanisms of miR-497 in regulation of cell growth and apoptosis in glioma cells. Three well-developed bioinformatics algorithms (RNAhybrid 2.1, TargetScan, and PicTar) predicted that miR-497 targets mTOR and Bcl-2 (Fig. 3A), which had been reported as targets in ovarian and breast cancer cells [12, 18]. To confirm whether endogenous mTOR and Bcl-2 are regulated by miR-497, the protein expression levels of mTOR and Bcl-2 were assessed in glioma cells transfected with miR-497, anti-miR-497 and their matched controls. The silencing of miR-497 decreased the protein levels of IGF1R/IRS1 pathway-related proteins, that is, IGF1R, IRS1, mTOR, and Bcl-2 (Fig. 3B). However, the levels of the above IGF1R/IRS1 signal pathway-related proteins were increased when U87 and SF295 cells were transfected with miR-497 (Fig. 3C).

MiR-497 increases TMZ resistance by targeting mTOR/Bcl-2

Our result revealed that the protein levels of IGF1R, IRS1, mTOR, and Bcl-2 were increased in TMZ-resistant glioma cells (U87-TR and SF295-TR) compared with TMZ-sensitive glioma cells (U87 and SF295) (Fig. 3D). Since mTOR and Bcl-2 were associated with the IGF1R/IRS1 signal pathway, along with the confirmation of mTOR and Bcl-2 are direct targets of miR-497. We hypothesized that miR-497 could regulate TMZ resistance in glioma cells by targeting IGF1R/IRS1 pathway. To verify this, we performed mTOR and Bcl-2 loss-of-function experiments in U87-TR and SF295-TR cells to investigate whether the silencing of mTOR and Bcl-2 in glioma cells could regulate the chemotherapy resistance of glioma cells in vitro. The knockdown of mTOR and Bcl-2 exerted a similar effect as depletion of miR-497 on reducing both glioma cell lines resistance to TMZ treatment (Fig. 3E). In addition, we further investigated the cellular apoptosis in mTOR and Bcl-2 knockdown U87-TR cells. Our results showed that the loss of mTOR and Bcl-2 increased the apoptotic cells induced by TMZ in U87-TR cells (Fig. 3F). Next, we successfully acquired
mTOR and Bcl-2-overexpressed glioma cells. Interestingly, enhanced levels of mTOR and Bcl-2 obviously abrogated the anti-resistant effect induced by anti-miR-497 (Fig. 4). These data showed that the up-regulation of miR-497 promotes acquisition of TMZ-resistant ability in glioma cell via promotion of IGF1R/IRS1 signal pathway-related proteins.

**MiR-497 increases TMZ resistance of glioma cells in vivo**

To indentify whether down-regulation of miR-497 in TMZ-resistant glioma cells could enhance the sensitivity of TMZ in vivo**, At the end of experiment, the subcutaneous xenograft tumors were excised and weighed. As shown in Figure 5A, consistent with the results obtained from the in vitro assays, the xenograft tumor weights were indicative of a significant decrease in the U87-TR/lenti-anti-miR-497 + TMZ (anti-miR-497 + TMZ) group in comparison with U87-TR/lenti-anti-NC + TMZ (anti-NC + TMZ) group. The level of miR-497 was down-regulated in anti-miR-497 + TMZ group tumor tissues than that in anti-NC + TMZ group tumor tissues (Fig. 5B).

**Immunohistochemical staining in vivo**

Then, the immunohistochemical detection of cell proliferation marker Ki-67 expression in the tumor tissues was performed. As indicated in Figure 5C, the percentage of Ki-67-positive stained cells was significantly higher in the tumor derived from anti-NC + TMZ group than its expression in the anti-miR-497 + TMZ group. In addition, quantitative data showed that TUNEL staining of these tissue sections indicated significant differences in the percentage of TUNEL-positive cells in the tumors derived from the anti-miR-497 + TMZ group compared with the anti-NC + TMZ group (Fig. 5D). Subsequently, the levels of mTOR and Bcl-2 in the xenograft tumors of both groups were examined by western blot. Our results demonstrated that the expression of mTOR and Bcl-2 were markedly decreased in U87-TR/lenti-anti-miR-497 cells formed tumors compared with that in U87-TR/lenti-anti-NC cells formed tumors at the translational level (Fig. 5E).

**Discussion**

Previous studies have demonstrated that miRNAs are up-regulated or down-regulated in glioma samples, and associated with histological subtypes, tumor stages, recurrent tumors, and overall survival [7, 12, 13, 19, 20]. Recently, increasing evidence also showed that miRNAs are involved in the regulation of glioma cells chemotherapy or radiotherapy resistance [21, 22]. However, to the best of our knowledge, there is limited information regarding the contribution that miRNAs make to the chemoresistance of glioma and the mechanisms of miRNAs in regulating resistance of TMZ in glioma remains poorly understood. In this study, qRT-PCR analysis showed that the expression of miR-497 is significantly up-regulated in several glioma cell lines in comparison with normal cells. The differential expression of miR-497 was indicative of the fact that miR-497 might be involved in the carcinogenesis of glioma. Our results are consistent with a recent study which demonstrated that miR-497 expression is associated with cervical cancer growth and as a novel noninvasive biomarker for detection of cervical cancer [16].

In this study, the level of miR-497 in glioma cells was interfered with an effort to explore the function of miR-497 on the TMZ resistance of glioma cells. Our results demonstrated that the level of miR-497 was markedly up-regulated in both TMZ-resistant glioma cell lines than their matched parental cell lines. Furthermore, CCK-8 assay and apoptosis assay supported our hypothesis that the down-regulation of miR-497 can enhance the cytotoxic effect of TMZ on glioma cells, and vice versa. Thus, our data were collectively suggestive of the idea that miR-497 plays a vital role in TMZ resistance of glioma cells in vitro. Further trials were employed to validate the hypothesis that the impact of miR-497 on the TMZ resistance of glioma is sustained in vivo. In vivo results showed that the down-regulation of miR-497 in U87-TR cells significantly increases TUNEL staining and decreases Ki-67 immunoreactivity, which is indicative of the apoptosis and reduced cellular proliferation within tumors, leading to...
Figure 3. MiR-497 directly targets mTOR and Bcl-2. (A) The putative miR-497 binding sequences in the 3′-UTR of mTOR and Bcl-2. (B) The levels of IGF1R, IRS1, mTOR, and Bcl-2 in U87-TR and SF295-TR cells after transfecing with anti-miR-497 were analyzed by western blot. (C) The expression of IGF1R, IRS1, mTOR, and Bcl-2 in U87 and SF295 cells was up-regulated by the transfection of miR-497. (D) Relative expression levels of IGF1R/IRS1 pathway-related proteins were increased in U87-TR and SF295-TR cells than their matched parental cell lines. (E) Knockdown of endogenous mTOR and Bcl-2 in U87-TR and SF295-TR cells markedly decreased TMZ-resistance of glioma cells. (F) Silencing of mTOR and Bcl-2 promoted the apoptosis of U87-TR cells induced by TMZ, the arrows shown the typical apoptotic cells. Results are reported as the mean ± SD of three independent experiments, **P < 0.01, ***P < 0.001. mTOR, mammalian target of rapamycin; 3′-UTR, 3′-untranslated region; IGF1R, insulin-like growth factor 1 receptor; IRS1, insulin receptor substrate 1; TMZ, temozolomide; SD, standard deviation.
a much better TMZ treatment effect on glioma xenograft tumor growth than control group. These in vitro and in vivo findings provides promising evidence supporting miR-497 as a valuable future target for glioma treatment, and miR-497 might be used as a “supplement” in TMZ-based chemotherapy. Applied TMZ with miR-497 antagonists may help to reduce the rate of TMZ-resistant glioma occurrence and improving the overall response rate to chemotherapy.

Numerous studies have demonstrated that the IGF1R/IRS1 pathway was involved in cell proliferation and metastasis control of several solid tumors [23, 24]. mTOR is associated with various biological processes including cell proliferation, differentiation, migration and invasion, angiogenesis, survival as well as tumorigenesis [25, 26]. Recent studies demonstrated that mTOR also plays an important role in chemotherapeutic resistance [27, 28]. Moreover, PI3K/Akt/mTOR signaling pathway is associated with prostate cancer radioresistance [29]. The Bcl-2 family proteins play a crucial role in apoptosis through the balance of pro-apoptotic proteins and anti-apoptotic proteins [30]. Bcl-2 has been shown to modulate chemosensitivity in several human cancers [31, 32]. Recent trials demonstrated that several miRs mediate chemotherapy resistance by targeting mTOR or Bcl-2 [12, 13, 15, 18, 30]. However, the association of miR-497 and chemosensitivity of IGF1R/IRS1 pathway has not yet been explored in glioma. Our results demonstrated that the down-regulation of miR-497 could inhibit the levels of IGF1R/IRS1 signal pathway-related proteins in TMZ-resistant glioma cells both in vitro and in vivo. Furthermore, overexpression of miR-497 markedly increased the expression of IGF1R/IRS1 signal pathway-related proteins in TMZ-sensitive glioma cells both in vitro and in vivo. Moreover, loss-of-function analyses disclosed that inhibition of mTOR and Bcl-2 suppresses the TMZ resistance of TMZ-resistant cells, consistent with the effects of miR-497 depletion in the same cells. In addition, our current finding showed that mTOR and Bcl-2 were regulated by miR-497 directly, highlighting the
potential role of miR-497 overexpression for glioma to develop a TMZ-resistance phenotype. We demonstrated that miR-497 could regulate TMZ resistance in glioma cells by promoting cell proliferation and inhibiting apoptosis, at least partially, via targeting the IGF1R/IRS1 pathway.

**Conclusion**

In conclusion, our results are consistent with the hypothesis that miR-497 as a glioma promoter, is significantly correlated with the TMZ resistance of human glioma cells by targeting the IGF1R/IRS1 pathway both in vitro and in vivo. Moreover, mTOR and Bcl-2 were identified as direct physiological targets of miR-497 with biological function that are implicated in the development of TMZ-resistance phenotype. This work highlights the therapeutic potential of miR-497 in the functional regulation of glioma.

**Conflict of Interest**

None declared.

**References**

1. Jungk, C., D. Chatzaslanidou, R. Ahmadi, D. Capper, J. L. Bermejo, J. Exner, et al. 2016. Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. BMC Cancer 16(1):81.
2. Wu, C. X., G. S. Lin, Z. X. Lin, J. D. Zhang, L. Chen, S. Y. Liu, et al. 2015. Peritumoral edema on magnetic resonance imaging predicts a poor clinical outcome in malignant glioma. Oncol Lett 10(5):2769–2776.
3. Li, B. O., C. Meng, X. Zhang, D. Cong, X. Gao, W. Gao, et al. 2016. Effect of photodynamic therapy combined with torasemine on the expression of matrix metalloproteinase 2 and sodium-potassium-chloride cotransporter 1 in rat peritumoral edema and glioma. Oncol Lett 11(3):2084–2090.

4. Lou, M., and Y. Zhao. 2015. Satisfactory therapy results of combining nimustine with nicardipine against glioma at advanced stage. J Cancer Res Ther 11(4):1030.

5. Tang, J. H., Z. X. Ma, G. H. Huang, Q. F. Xu, Y. 4. Lou, M., and Y. Zhao. 2015. Satisfactory therapy results of combining nimustine with nicardipine against glioma at advanced stage. J Cancer Res Ther 11(4):1030.

6. Shi, L., X. Fei, Z. Wang, and Y. You. 2015. PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cell cancer effects through inactivation of Wnt/β-catenin signaling pathway. Vitro Cell Dev Biol Anim 51(10):1047–1055.

7. Burri, S. H., R. S. Prabhu, A. L. Sumrall, W. Brick, B. D. Blaker, B. E. Jr Heideman, et al. 2015. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial. J Neurooncol 123(2):259–266.

8. Castro, G. N., N. Cayado-Gutiérrez, F. C. Zoppino, M. A. Fanelli, F. D. Cuello-Carrion, M. Sottile, et al. 2015. Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells. Cell Stress Chaperones 20(2):253–265.

9. Yu, X., W. Zhao, X. Yang, Z. Wang, and M. Hao. 2016. miR-375 Affects the Proliferation, Invasion, and Apoptosis of HPV16-Positive Human Cervical Cancer Cells by Targeting IGF1R. Int J Gynecol Cancer 26(5):857–865.

10. MacLean, J. A., M. L. King, H. Okuda, and K. Hayashi. 2016. WNT7A Regulation by miR-15b in Ovarian Cancer. PLoS One 11(5):e0156109.

11. Chen, X., Y. Zhang, Y. Shi, H. Lian, H. Tu, S. Han, et al. 2015. MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2. Int J Oncol 47(4):1603–1611.

12. Han, J., and Q. Chen. 2015. MiR-16 modulate temozolomide resistance by regulating Bcl-2 in human glioma cells. Int J Clin Exp Pathol 8(10):12698–12707.

13. Wu, Z., X. Cai, C. Huang, J. Xu, and A. Liu. 2016. miR-497 suppresses angiogenesis in breast carcinoma by targeting HIF-1α. Oncol Rep 35(3):1696–1702.

14. Xu, S., G. B. Fu, Z. Tao, J. OuYang, F. Kong, B. H. Jiang, et al. 2015. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget 6(28):26457–26471.

15. Zhang, Y., D. Zhang, F. Wang, D. Xu, Y. Guo, and W. Cui. 2015. Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer. Sci Rep 5:17942.

16. Du, M., D. Shi, L. Yuan, P. Li, H. Chu, C. Qin, et al. 2015. Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer. Sci Rep 5:10437.

17. Wei, C., Q. Luo, X. Sun, D. Li, H. Song, X. Li, et al. 2015. microRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer. Int J Clin Exp Pathol 8(7):7729–7739.

18. Zheng, G. D., Y. U. Wang, and X. D. Zhu. 2016. Evaluation of miR-302c-3p as prognostic biomarkers in glioma patients. Eur Rev Med Pharmacol Sci 20(8):1521–1525.

19. Sakr, M., T. Takino, H. Sabit, M. Nakada, Z. Li, and H. Sato. 2016. miR-150-5p and miR-133a suppress glioma cell proliferation and migration through targeting membrane-type-1 matrix metalloproteinase. Gene 587(2):155–162.

20. Wang, X., M. Wang, H. Li, X. Lan, L. Liu, J. Li, et al. 2015. Upregulation of miR-497 induces hepatic insulin resistance in E3 rats with HFD-Mets by targeting insulin receptor. Mol Cell Endocrinol 416:57–69.

21. Shao, X. J., M. H. Miao, J. Xue, J. Xue, X. Q. Ji, and H. Zhu. 2015. The Down-Regulation of MicroRNA-497 Contributes to Cell Growth and Cisplatin Resistance Through PI3K/Akt Pathway in Osteosarcoma. Cell Physiol Biochem 36(5):2051–2062.

22. Yang, M., X. Shan, X. Zhou, T. Qiu, W. Zhu, Y. Ding, et al. 2014. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting membrane-tyoe-1 matrix metalloproteinase. Int J Clin Exp Pathol 7(4):e36190.

23. Abbondanza, R. Malekzadeh, et al. 2012. The insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer. PLoS One 7(4):e36190.

24. Kao, C. C., J. S. Liu, M. H. Lin, C. Y. Hsu, F. C. Chang, Y. C. Lin, et al. 2016. Impact of mTOR Inhibitors on Cancer Development in Kidney Transplantation Recipients: A Population-Based Study. Transplant Proc 48(3):900–904.
26. Heits, N., T. Heinze, A. Bernsmeier, J. Kerber, C. Hauser, T. Becker, et al. 2016. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer-associated fibroblasts. BMC Cancer 16(1):322.
27. Allen, E., P. Miéville, C. M. Warren, S. Saghafinia, L. Li, M. W. Peng, et al. 2016. Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTORSignaling. Cell Rep 15(6):1144–1160.
28. Leroy, C., P. Ramos, K. Cornille, D. Bonenfant, C. Fritsch, H. Voshol, et al. 2016. Activation of IGF1R/ p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition. Breast Cancer Res 18(1):41.
29. Chang, L., P. H. Graham, J. Ni, J. Hao, J. Bucci, P. J. Cozzi, et al. 2015. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Crit Rev Oncol Hematol 96(3):507–517.
30. Stojcheva, N., G. Schechtmann, S. Sass, P. Roth, A. M. Florea, A. Stefanski, et al. 2016. MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. Oncotarget 7(11):12937–12950.
31. Leisching, G., B. Loos, M. Botha, and A. M. Engelbrecht. 2015. Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance. J Transl Med 13:328.
32. Song, T., G. Chai, Y. Liu, X. Yu, Z. Wang, and Z. Zhang. 2016. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. Br J Pharmacol 173(3):471–483.